Therapeutic | Ustekinumab |
Target | IL12B |
Heavy Chain | EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRYSPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPYTFGQGTKLEIK |
100% seqID Fv Structure | 3hmw [Fvs: HL], 3hmx [Fvs: HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 3hmw [Fvs: HL] |
100% seqID Structure | 3hmx [Fvs: HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | Medarex UltiMAb Mouse |
INN Year Proposed | 2008 |
INN Year Recommended | 2009 |
Companies Involved | Centocor Inc, Janssen Biotech, Medarex |
Conditions Approved | Crohn's disease, Plaque psoriasis, Psoriatic arthritis |
Conditions Active | Ulcerative colitis, Spondylarthritis, Systemic lupus erythematosus, Atopic dermatitis |
Conditions Discontinued | Multiple sclerosis, Palmoplantar pustulosis, Primary biliary cirrhosis, Rheumatoid arthritis, Sarcoidosis |
Notes |